Stock comparison
Halozyme Therapeutics
Koninklijke Philips N.V.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
PHG
Koninklijke Philips N.V.
Market cap
$25.66B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | PHG | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 38D | HALO |
| Benjamin Graham | 83A | 36D | HALO |
| Philip Fisher | 65B | 38D | HALO |
| Peter Lynch | 53D | 44D | HALO |
| Joel Greenblatt | 40D | 30F | HALO |
| Charlie Munger | 80C | 36D | HALO |
| Terry Smith | 84A | 33F | HALO |
Side-by-side metrics
| Metric | HALO | PHG |
|---|---|---|
| Market cap | $8.1B | $25.66B |
| P/E (TTM) | 24.0x | 21.4x |
| EV/EBIT | 10.2x | 18.5x |
| ROIC (TTM) | 23.65% | 5.76% |
| Gross margin | 81.24% | 45.2% |
| Net margin | 23.13% | 5.5% |
| Revenue CAGR 5y | 33.23% | 0.97% |
| EPS CAGR 5y | -1.98% | 9.12% |
| Debt / Equity | 1.0x | 0.7x |
| Dividend yield | 0.0% | 3.89% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 0.97%+97%
- Net margin23.13%vs 5.5%+76%
- ROIC (TTM)23.65%vs 5.76%+76%
- EV/EBIT10.2xvs 18.5x+45%
PHG leads on
- EPS CAGR 5y9.12%vs -1.98%+122%
- Dividend yield3.89%vs 0.0%+100%
- Market cap$25.66Bvs $8.1B+68%
- Debt / Equity0.7xvs 1.0x+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.